WO2003055916A3 - Adiponectin fragments and conjugates - Google Patents
Adiponectin fragments and conjugates Download PDFInfo
- Publication number
- WO2003055916A3 WO2003055916A3 PCT/DK2002/000897 DK0200897W WO03055916A3 WO 2003055916 A3 WO2003055916 A3 WO 2003055916A3 DK 0200897 W DK0200897 W DK 0200897W WO 03055916 A3 WO03055916 A3 WO 03055916A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adiponectin
- polypeptide
- amino acid
- acid residue
- conjugate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002358467A AU2002358467A1 (en) | 2001-12-21 | 2002-12-20 | Adiponectin fragments and conjugates |
JP2003556446A JP2005526492A (en) | 2001-12-21 | 2002-12-20 | Adiponectin fragments and conjugates |
EP02792711A EP1458758A2 (en) | 2001-12-21 | 2002-12-20 | Adiponectin fragments and conjugates |
US10/498,665 US20060052292A1 (en) | 2001-12-21 | 2002-12-20 | Adiponectin fragments and conjugates |
CA002468619A CA2468619A1 (en) | 2001-12-21 | 2002-12-20 | Adiponectin fragments and conjugates |
Applications Claiming Priority (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34348201P | 2001-12-21 | 2001-12-21 | |
DKPA200101952 | 2001-12-21 | ||
US60/343,482 | 2001-12-21 | ||
DKPA200101952 | 2001-12-21 | ||
US37549202P | 2002-04-25 | 2002-04-25 | |
DKPA200200627 | 2002-04-25 | ||
US60/375,492 | 2002-04-25 | ||
DKPA200200627 | 2002-04-25 | ||
US39411702P | 2002-07-03 | 2002-07-03 | |
DKPA200201036 | 2002-07-03 | ||
DKPA200201036 | 2002-07-03 | ||
US60/394,117 | 2002-07-03 | ||
US41216902P | 2002-09-20 | 2002-09-20 | |
DKPA200201385 | 2002-09-20 | ||
DKPA200201385 | 2002-09-20 | ||
US60/412,169 | 2002-09-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003055916A2 WO2003055916A2 (en) | 2003-07-10 |
WO2003055916A3 true WO2003055916A3 (en) | 2003-12-31 |
Family
ID=27570813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2002/000897 WO2003055916A2 (en) | 2001-12-21 | 2002-12-20 | Adiponectin fragments and conjugates |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1458758A2 (en) |
JP (1) | JP2005526492A (en) |
AU (1) | AU2002358467A1 (en) |
CA (1) | CA2468619A1 (en) |
WO (1) | WO2003055916A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ534699A (en) | 2002-01-18 | 2008-12-24 | Protemix Corp Ltd | Glycoisoforms of adiponectin and uses thereof |
EP1506229A1 (en) * | 2002-05-17 | 2005-02-16 | Serono Genetics Institute S.A. | Obg3 fragments inhibiting the conversion of active obg3 into less active obg3 and other compositions for treatment of metabolic disorders |
DE60333917D1 (en) * | 2002-05-31 | 2010-10-07 | Serono Genetics Inst Sa | HOMOTRIMERER, EXTENDED GLOBULAR HEAD OF OBG3 AND USES THEREOF |
US7176292B2 (en) * | 2003-09-11 | 2007-02-13 | Dialean, Ltd. | Ghrelin variant protein |
US20080139468A1 (en) * | 2004-03-31 | 2008-06-12 | Kazuhisa Maeda | Method For Control of Invasion and Use of Adiponectin |
WO2006061853A2 (en) * | 2004-12-10 | 2006-06-15 | Serum Institute Of India Limited | Novel erythropoietic compounds and a process for producing erythropoietic compounds |
US7592423B2 (en) | 2005-01-07 | 2009-09-22 | Xencor, Inc. | Globular adiponectin variants |
US7749956B2 (en) | 2005-01-07 | 2010-07-06 | Xencor, Inc. | Method of treatment using adiponectin variants |
AU2006203832A1 (en) * | 2005-01-07 | 2006-07-13 | Xencor | Adiponectin variants |
WO2006104964A2 (en) * | 2005-03-28 | 2006-10-05 | University Of Louisville Research Foundation, Inc. | Inhibition of wet type age related macular degeneration (amd) by adiponectin or acrp 30 |
CN1740195B (en) * | 2005-04-15 | 2012-01-04 | 复旦大学 | Polypeptide gapM1 and its prepn process |
US7709607B2 (en) | 2005-07-11 | 2010-05-04 | Xencor, Inc. | Adiponectin variants |
WO2007008937A2 (en) * | 2005-07-11 | 2007-01-18 | Xencor | Adiponectin variants |
JP2009502849A (en) * | 2005-07-29 | 2009-01-29 | ラボラトワール セローノ ソシエテ アノニム | Use of ACRP30 for the treatment and / or prevention of thrombosis and cancer |
EP1981526A4 (en) * | 2006-01-09 | 2011-03-02 | Childrens Hosp Medical Center | Adiponectin for treatment of various disorders |
WO2008067599A1 (en) * | 2006-12-04 | 2008-06-12 | Apollo Life Sciences Limited | Isolated leptin and adiponectin molecules and chimeric molecules thereof |
US8026345B2 (en) * | 2007-01-08 | 2011-09-27 | Hoffmann-La Roche Inc. | Characterization and identification of unique human adiponectin isoforms and antibodies |
CN103228290A (en) | 2011-02-18 | 2013-07-31 | (株)斯坦帝尔 | Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock |
CN104004066B (en) * | 2013-02-26 | 2017-05-31 | 上海市第一人民医院 | Prevention suppresses inflammatory reaction and micromolecule polypeptide and its application of angiogenesis |
WO2018004067A1 (en) * | 2016-07-01 | 2018-01-04 | 전남대학교 산학협력단 | Adiponectin overexpression cell line |
CN112209995B (en) * | 2020-10-14 | 2022-01-11 | 华兰基因工程有限公司 | Preparation method of SARS-CoV-2 surface protein receptor binding region |
CN112521481B (en) * | 2020-12-08 | 2022-11-04 | 武汉市工程科学技术研究院 | Surface modifier and preparation method and application thereof |
CN112574306B (en) * | 2020-12-17 | 2023-05-05 | 武汉华美生物工程有限公司 | Adiponectin monoclonal antibody, antibody pair, preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0152847A1 (en) * | 1984-02-03 | 1985-08-28 | Abbott Laboratories | Stabilized enzyme conjugate composition |
WO2001051645A1 (en) * | 2000-01-14 | 2001-07-19 | Genset | Obg3 globular head and uses thereof for decreasing body mass |
-
2002
- 2002-12-20 EP EP02792711A patent/EP1458758A2/en not_active Withdrawn
- 2002-12-20 AU AU2002358467A patent/AU2002358467A1/en not_active Abandoned
- 2002-12-20 WO PCT/DK2002/000897 patent/WO2003055916A2/en not_active Application Discontinuation
- 2002-12-20 CA CA002468619A patent/CA2468619A1/en not_active Abandoned
- 2002-12-20 JP JP2003556446A patent/JP2005526492A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0152847A1 (en) * | 1984-02-03 | 1985-08-28 | Abbott Laboratories | Stabilized enzyme conjugate composition |
WO2001051645A1 (en) * | 2000-01-14 | 2001-07-19 | Genset | Obg3 globular head and uses thereof for decreasing body mass |
Non-Patent Citations (11)
Title |
---|
BERG A H ET AL: "The adipocyte-secreted protein Acrp30 enhances hepatic insulin action.", NATURE MEDICINE. UNITED STATES AUG 2001, vol. 7, no. 8, August 2001 (2001-08-01), pages 947 - 953, XP002242789, ISSN: 1078-8956 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1988, FORMANOWSKI F ET AL: "ISOLATION OF THE INFLUENZA C VIRUS GLYCOPROTEIN IN A SOLUBLE FORM BY BROMELAIN DIGESTION", XP002255332, Database accession no. PREV198886054594 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992, LANZA F ET AL: "DIFFERENTIAL EFFECTS OF EXTRA AND INTRACELLULAR CALCIUM CHELATION ON HUMAN PLATELET FUNCTION AND GLYCOPROTEIN IIB-IIIA COMPLEX STABILITY", XP002255334, Database accession no. PREV199294001032 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, CASTON JOSE R ET AL: "S-layer protein from Thermus thermophilus HB8 assembles into porin-like structures.", XP002255333, Database accession no. PREV199396092136 * |
FRUEBIS J ET AL: "Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 13 FEB 2001, vol. 98, no. 4, 13 February 2001 (2001-02-13), pages 2005 - 2010, XP002242791, ISSN: 0027-8424 * |
MOLECULAR MICROBIOLOGY, vol. 9, no. 1, 1993, pages 65 - 75, ISSN: 0950-382X * |
NOUVELLE REVUE FRANCAISE D'HEMATOLOGIE, vol. 34, no. 1, 1992, pages 123 - 131, ISSN: 0029-4810 * |
SHAPIRO L ET AL: "The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor.", CURRENT BIOLOGY: CB. ENGLAND 12 MAR 1998, vol. 8, no. 6, 12 March 1998 (1998-03-12), pages 335 - 338, XP002242793, ISSN: 0960-9822 * |
VIRUS RESEARCH, vol. 10, no. 2-3, 1988, pages 177 - 192, ISSN: 0168-1702 * |
WANG YU ET AL: "Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 31 MAY 2002, vol. 277, no. 22, 31 May 2002 (2002-05-31), pages 19521 - 19529, XP002242790, ISSN: 0021-9258, Retrieved from the Internet <URL:http://www.jbc.org/cgi/content/full/277/22/19521> [retrieved on 20030528] * |
YAMAUCHI T ET AL: "The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.", NATURE MEDICINE. UNITED STATES AUG 2001, vol. 7, no. 8, August 2001 (2001-08-01), pages 941 - 946, XP002242792, ISSN: 1078-8956 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003055916A2 (en) | 2003-07-10 |
AU2002358467A1 (en) | 2003-07-15 |
EP1458758A2 (en) | 2004-09-22 |
CA2468619A1 (en) | 2003-07-10 |
JP2005526492A (en) | 2005-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003055916A3 (en) | Adiponectin fragments and conjugates | |
YU48703A (en) | New interferon beta-like molecules | |
WO2001051510A3 (en) | G-csf conjugates | |
WO2005055950A3 (en) | Glycopegylated factor ix | |
WO2006116475A3 (en) | Immunostimulatory compositions | |
WO2006031811A3 (en) | Glycopegylated interferon alpha | |
WO2006127896A3 (en) | Glycopegylated factor ix | |
WO2001079464A3 (en) | Nucleic acids encoding polypeptides having haloperoxidase activity | |
WO2005051327A3 (en) | Glycopegylated erythropoietin | |
EP1329458A3 (en) | Peptides that lower blood glucose levels | |
CA2171882A1 (en) | Inhibitors of .beta.-amyloid protein production | |
WO2001058935A3 (en) | FACTOR VII OR VIIa-LIKE MOLECULES | |
WO2003008444A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
WO2002055532A3 (en) | Variant growth hormone molecules conjugated with macromolecular compounds | |
WO2002032461A3 (en) | Protein c or activated protein c-like molecules | |
WO2001015736A3 (en) | Interferon-beta conjugates | |
WO2002040037A3 (en) | M. tuberculosis chaperonin 60.1 and uses thereof | |
WO1998019697A3 (en) | Novel pharmaceutical compositions | |
WO2001010408A3 (en) | Aqueous pharmaceutical composition containing moxifloxacin or salts thereof | |
WO2001042474A3 (en) | Interferon-like molecules and uses thereof | |
AU2002309122A1 (en) | Compositions based on branched chain amino acids for improving the myocardial ventricular function in patients suffering from diabetes | |
WO2004074454A3 (en) | Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes | |
WO2003020963A3 (en) | Proteins in type 2 diabetes | |
EP2275118A3 (en) | Pancreas-specific proteins | |
CA2205771A1 (en) | Improved delivery of disease modifiers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2468619 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003556446 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002792711 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1579/CHENP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002358467 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002792711 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006052292 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10498665 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10498665 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002792711 Country of ref document: EP |